Schizophrenia Clinical Trial
Official title:
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
The purpose of this study is to assess the efficacy of d-cycloserine (DCS) as an augmentation
strategy in two psychotic patients with a triplication (4 copies) of the glycine
decarboxylase (GLDC) gene. Subjects will first undergo an eight-week open-label arm of
treatment with DCS (50 mg/d) followed by six 6-week double-blind placebo-controlled exposures
to DCS or placebo. The length of each double-blind arm is limited to six weeks to minimize
the length of symptom exacerbation experienced by the subjects when they are receiving
placebo. The randomization scheme will allow two consecutive exposures to DCS, but will not
allow two consecutive exposures to placebo, again to minimize the length of any symptom
exacerbation. At the end of the open-label DCS trial, the following procedures will be
carried out: structural MRI (3T), proton 1H MRS (4T), fMRI (3T), steady-state auditory evoked
potentials, and electroretinogram recordings. In addition, 1H MRS (4T) for 2 hours after a
single oral dose of a DCS will be assessed. Baseline data on all of these measures were
previously obtained as part of a different study registered in clinical trials.gov -
NCT01720316). Positive, negative, and affective symptoms and neurocognitive function as well
as plasma levels of large neutral and large and small neutral and excitatory amino acids and
psychotropic drug levels will be assessed periodically. Pharmaceutical grade DCS) or placebo
will be compounded and dispensed by the McLean Hospital Pharmacy.
The investigators hypothesize that mutation carriers will have reduced endogenous brain
glycine and GABA levels and increased brain glutamate and glutamine levels. DCS
administration will increase brain glycine in the two carriers compared to baseline and
treatment with glycine (0.8g/kg).
The investigators hypothesize reduced activation of magnocellular pathways and abnormal ERPs
modulated by NMDA in mutation carriers compared with non-carrier family members and controls.
. The investigators hypothesize that DCS, but not placebo, will improve positive, negative
and affective symptoms as well as neurocognitive function.
The investigators also hypothesize that DCS will improve clinical and cognitive functioning,
will partially normalize decreased baseline glycine and GABA and increased glutamate and
glutamine, and will partially normalize magnocellular pathway activation and abnormal evoked
potentials.
Multiple rare structural variants of relatively recent evolutionary origin are recognized as
important risk factors for schizophrenia (SZ) and other neurodevelopmental disorders (e.g.,
autism spectrum disorders, mental retardation, epilepsy) with odds ratios as high as 7-30. We
have found a de novo structural rearrangement on chromosome 9p24.1 in two psychotic patients.
One of the genes in this region is the gene encoding glycine decarboxylase (GLDC), which
affects brain glycine metabolism. GLDC encodes the glycine decarboxylase or glycine cleavage
system P-protein, which is involved in degradation of glycine in glia cells. Carriers of the
GLDC triplication would be expected to have low levels of brain Gly, resulting in NMDA
receptor-mediated hypofunction, which has been strongly implicated in the pathophysiology of
schizophrenia.
There is an extensive literature on the effects of NMDA enhancing agents on positive,
negative, and depressive symptoms and on neurocognitive function. Although many studies have
reported positive results in at least one symptom domain, the results of other studies have
been negative or ambiguous. Factors likely to contribute to this variability include:
mechanism of action of the agent, compliance, concurrent treatment with first- vs second
generation antipsychotic drugs, baseline glycine blood levels, presence/absence of kynurenine
pathway metabolic abnormalities and individual differences in brain glycine uptake and
metabolism . Genetic variants that impact the synthesis and breakdown of glycine, glutamate,
or other modulators of NMDA receptor function are also likely to have significant effects.
Although DCS augmentation has shown variable efficacy in patients unselected for having a
mutation that would be expected to lower brain glycine levels, the GLDC triplication in the
two carriers in this study would be expected to result in unusually low brain glycine levels,
supporting its therapeutic potential as an augmentation strategy.
Thus, it is important to evaluate the therapeutic efficacy of DCS augmentation in individuals
in whom there is a high prior probability of therapeutic benefit and to characterize the
neurobiology of this mutation in terms of brain metabolites, brain function, and the
pharmacokinetics of glycine metabolism using well-established methods.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |